KCND3

A-type voltage-gated potassium channel KCND3 · Q9UK17 · KCND3 on Sugi Atlas →

15,987 patent compounds predicted against KCND3, 12,516 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1378480	0.69	2/20
SCHEMBL1376015	0.50	2/20
SCHEMBL1243098	0.46	2/20
SCHEMBL1377652	0.45	2/20
SCHEMBL1377762	0.43	2/20
SCHEMBL1378615	0.41	2/20
SCHEMBL1379567	0.40	2/20
SCHEMBL1379399	0.40	2/20
SCHEMBL1380487	0.39	2/20
Tolterodine (SCHEMBL3064)	1.00	1/20
Duloxetine (SCHEMBL3803)	1.00	1/20
Vardenafil (SCHEMBL5772)	1.00	1/20
Duloxetine (SCHEMBL8291)	1.00	1/20
Nebivolol (SCHEMBL19863)	1.00	1/20
Nebivolol (SCHEMBL19864)	1.00	1/20
Tolterodine (SCHEMBL36882)	1.00	1/20
Darifenacin (SCHEMBL56574)	1.00	1/20
Deferasirox (SCHEMBL61756)	1.00	1/20
Paliperidone (SCHEMBL67205)	1.00	1/20
Acacetin (SCHEMBL107712)	1.00	1/20

Clinical trials — most relevant to KCND3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Peripheral KV7 Activation for Pain Relief	EARLY_PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KCND3 binder may also engage these)

Protein	Name	Similarity
Q9Z0V1	—	1.000	Q9Z0V1 →
Q62897	—	1.000	Q62897 →
Q9TTT5	—	1.000	Q9TTT5 →
Q9Z0V2	—	1.000	Q9Z0V2 →
Q63881	—	1.000	Q63881 →
Q8HYZ1	—	1.000	Q8HYZ1 →
P59995	—	1.000	P59995 →
KCND2	A-type voltage-gated potassium channel KCND2	1.000	landscape →
Q52PG9	—	0.993	Q52PG9 →
P17971	—	0.992	P17971 →
Q03717	—	0.992	Q03717 →
Q03719	—	0.991	Q03719 →
A6H8H5	—	0.990	A6H8H5 →
Q63099	—	0.990	Q63099 →
O18868	—	0.990	O18868 →
P25122	—	0.989	P25122 →
KCNB1	Potassium voltage-gated channel subfamily B member 1	0.989	landscape →
Q95167	—	0.989	Q95167 →
Q9MZ19	—	0.989	Q9MZ19 →
HCN1	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1	0.987	landscape →
P17972	—	0.987	P17972 →
Q60603	—	0.987	Q60603 →
Q4ZHA6	—	0.987	Q4ZHA6 →
P15387	—	0.987	P15387 →
Q9XXD1	—	0.987	Q9XXD1 →
Q9NSA2	—	0.986	Q9NSA2 →
Q14B80	—	0.985	Q14B80 →
P59994	—	0.985	P59994 →
O88704	—	0.985	O88704 →
Q8NCM2	—	0.984	Q8NCM2 →